Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

20051,823 citationsJournal Articlebronze Open Access

Authors

Timothy Winton · Ontario Institute for Cancer Research

Robert B. Livingston

David C. Johnson · Eastern Cooperative Oncology Group

James R. Rigas · Leukemia Research Foundation

Abstract

Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 25, pp. 2589-2597

DOI: 10.1056/nejmoa043623

Field-Weighted Citation Impact: 103.33